Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $17 | $26 | $21 |
| - Cash | $2 | $6 | $12 | $29 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $11 | $14 | -$9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$6 | -$13 | -$23 | -$13 |
| % Margin | – | – | – | – |
| Net Income | -$6 | -$13 | -$32 | -$13 |
| % Margin | – | – | – | – |
| EPS Diluted | -86.85 | -0.057 | -221.55 | -930 |
| % Growth | -152,268.4% | 100% | 76.2% | – |
| Operating Cash Flow | -$5 | -$13 | -$18 | -$10 |
| Capital Expenditures | $0 | -$0 | -$2 | $0 |
| Free Cash Flow | -$5 | -$13 | -$19 | -$10 |